Immuneering (IMRX) Projected to Post Earnings on Tuesday

Key Points

• Immuneering (NASDAQ:IMRX) is set to announce its Q2 2025 earnings on August 5th, with analysts predicting an earnings per share (EPS) of ($0.40).
• In its last earnings report, Immuneering missed expectations with an EPS of ($0.42), compared to the consensus estimate of ($0.41).
• Recent analyst updates include Oppenheimer lowering its price target to $21.00 while Chardan Capital maintains a price target of $13.00, with a majority rating of "buy".

Immuneering (NASDAQ:IMRX - Get Free Report) is anticipated to release its Q2 2025 earnings data before the market opens on Tuesday, August 5th. Analysts expect the company to announce earnings of ($0.40) per share for the quarter.

Immuneering (NASDAQ:IMRX - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.01). On average, analysts expect Immuneering to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Immuneering Trading Down 1.4%

Shares of NASDAQ:IMRX traded down $0.05 during trading on Wednesday, hitting $3.63. 232,628 shares of the company's stock were exchanged, compared to its average volume of 738,376. The firm has a market cap of $130.64 million, a P/E ratio of -1.85 and a beta of 0.38. The firm has a 50-day moving average price of $3.00 and a two-hundred day moving average price of $2.08. Immuneering has a 1-year low of $1.00 and a 1-year high of $4.69.

Analyst Upgrades and Downgrades

IMRX has been the topic of a number of analyst reports. Chardan Capital reissued a "buy" rating and issued a $13.00 price target on shares of Immuneering in a research note on Wednesday, June 18th. Mizuho raised their target price on Immuneering from $8.00 to $10.00 and gave the stock an "outperform" rating in a report on Wednesday, June 18th. Needham & Company LLC reaffirmed a "buy" rating and issued a $9.00 price target on shares of Immuneering in a research note on Wednesday, June 18th. Finally, Oppenheimer reduced their price objective on shares of Immuneering from $25.00 to $21.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $13.25.

Insiders Place Their Bets

In related news, Director Peter Feinberg acquired 25,000 shares of the stock in a transaction dated Wednesday, June 18th. The stock was bought at an average price of $2.53 per share, with a total value of $63,250.00. Following the completion of the transaction, the director directly owned 136,766 shares of the company's stock, valued at approximately $346,017.98. The trade was a 22.37% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Benjamin J. Zeskind bought 21,000 shares of Immuneering stock in a transaction that occurred on Wednesday, June 18th. The stock was bought at an average cost of $2.39 per share, with a total value of $50,190.00. Following the completion of the purchase, the chief executive officer owned 2,302,852 shares in the company, valued at approximately $5,503,816.28. This trade represents a 0.92% increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 127,507 shares of company stock worth $334,318. Company insiders own 22.90% of the company's stock.

Hedge Funds Weigh In On Immuneering

An institutional investor recently bought a new position in Immuneering stock. Jane Street Group LLC purchased a new position in shares of Immuneering Corporation (NASDAQ:IMRX - Free Report) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 20,869 shares of the company's stock, valued at approximately $32,000. Jane Street Group LLC owned 0.06% of Immuneering at the end of the most recent quarter. Institutional investors own 67.65% of the company's stock.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.